Ligand to Report First Quarter Results on May 10th

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2011 financial results on Tuesday, May 10, 2011, following the close of market. Ligand’s President and CEO, John Higgins, Executive Vice President and Chief Operating Officer, Matthew Foehr and Vice President of Finance and CFO, John Sharp will host the conference call.

First Quarter Earnings Call

What:       Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates
 
When: Tuesday, May 10, 2011
 
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
 
Webcast:

Conference call and replay accessible at www.ligand.com

 
Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
 
Replay: (877) 660-6853, Account #: 361 passcode: 371521
(201) 612-7415 outside the U.S.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Bristol-Myers Squibb and AstraZeneca. For more information, please visit www.ligand.com.



CONTACT:

Ligand Pharmaceuticals Incorporated
Rob McKay, Sr. Dir. Business Development
and Investor Relations
Erika Luib, Investor Relations
858-550-7896
or
Lippert/Heilshorn & Associates, Inc.
Don Markley
310-691-7100
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.